lMEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug.
Spray
EXCIPIENTS:May contain Gelatin, gentamicin
▶Fluenz Tetra(AstraZeneca UK Ltd)A
Fluenz Tetra vaccine nasal suspension 0. 2 ml unit dose| 10 unit
doseP£ 180. 00
Suspension for injection
EXCIPIENTS:May contain Gentamicin, kanamycin, neomycin penicillins,
polymyxin b
▶Influenza vaccine (Non-proprietary)
Influenza vaccine (split virion, inactivated) suspension for injection
0. 5 ml pre-filled syringes| 1 pre-filled disposable injectionP
£ 5. 22 – £ 6. 59 | 10 pre-filled disposable injectionP£ 52. 20 – £ 65. 90
Quadrivalent vaccine (split virion, inactivated) suspension for injection
0. 5 ml pre-filled syringes| 1 pre-filled disposable injectionP
£ 8. 00 | 10 pre-filled disposable injectionP£ 80. 00
▶Agrippal(Seqirus Vaccines Ltd)
Agrippal vaccine suspension for injection 0. 5 ml pre-filled syringes|
1 pre-filled disposable injectionP£ 6. 59 | 10 pre-filled disposable
injectionP£ 65. 90
▶Enzira(Pfizer Ltd)
Enzira vaccine suspension for injection 0. 5 ml pre-filled syringes|
1 pre-filled disposable injectionP£ 5. 25 | 10 pre-filled disposable
injectionP£ 52. 50
▶Fluarix Tetra(GlaxoSmithKline UK Ltd)A
Fluarix Tetra vaccine suspension for injection 0. 5 ml pre-filled syringes
| 1 pre-filled disposable injectionP£ 9. 94 | 10 pre-filled
disposable injectionP£ 99. 40
▶Imuvac(Mylan)
Imuvac vaccine suspension for injection 0. 5 ml pre-filled syringes|
1 pre-filled disposable injectionP£ 6. 59 | 10 pre-filled disposable
injectionP£ 65. 90
▶Influvac Sub-unit(Mylan)
Influvac Sub-unit vaccine suspension for injection 0. 5 ml pre-filled
syringes| 1 pre-filled disposable injectionP£ 5. 22 | 10 pre-filled
disposable injectionP£ 52. 20
eiiiiF 788Japanese encephalitis vaccine
lINDICATIONS AND DOSE
Immunisation against Japanese encephalitis
▶BY INTRAMUSCULAR INJECTION
▶Child 2 months–2 years: 0. 25 mL every 28 days for
2 doses, anterolateral thigh is preferred site of injection
in infants, the subcutaneous route may be used for
patients with bleeding disorders
▶Child 3–17 years: 0. 5 mL every 28 days for 2 doses,
deltoid muscle is preferred site in older children;
anterolateral thigh is preferred in infants, the
subcutaneous route may be used for patients with
bleeding disorderslSIDE-EFFECTSAbdominal pain.cough.influenza like
illness
lPREGNANCYAlthough manufacturer advises avoid
because of limited information, miscarriage has been
associated with Japanese encephalitis virus infection
acquired during thefirst 2 trimesters of pregnancy.
lMEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug.
Solution for injection
▶Japanese encephalitis vaccine (Non-proprietary)
Japanese encephalitis GCVC vaccine solution for injection 1 ml vials|
1 vials
Japanese encephalitis GCVC vaccine solution for injection 20 ml vials|
1 vials
Japanese encephalitis GCVC vaccine solution for injection 10 ml vials|
1 vials
Suspension for injection
▶Ixiaro(Valneva UK Ltd)
Ixiaro vaccine suspension for injection 0. 5 ml pre-filled syringes|
1 pre-filled disposable injectionP£ 59. 50
eiiiiF 788Measles, mumps and rubella vaccine,
live
lINDICATIONS AND DOSE
Primary immunisation against measles, mumps, and
rubella (first dose)
▶BY INTRAMUSCULAR INJECTION, OR BY DEEP SUBCUTANEOUS
INJECTION
▶Child 12–13 months: 0. 5 mL for 1 dose
Primary immunisation against measles, mumps, and
rubella (second dose)
▶BY INTRAMUSCULAR INJECTION, OR BY DEEP SUBCUTANEOUS
INJECTION
▶Child 40 months–5 years: 0. 5 mL for 1 dose
Rubella immunisation (in seronegative women,
susceptible to rubella and in unimmunised, seronegative
women, post-partum)
▶BY INTRAMUSCULAR INJECTION, OR BY DEEP SUBCUTANEOUS
INJECTION
▶Females of childbearing potential:(consult product
literature or local protocols)
Children presenting for pre-school booster, who have not
received the primary immunisation (first dose)|
Immunisation for patients at school-leaving age or at
entry into further education, who have not completed
the primary immunisation course|Control of measles
outbreak|Immunisation for patients travelling to areas
where measles is endemic or epidemic, who have not
completed the primary immunisation
▶BY INTRAMUSCULAR INJECTION, OR BY DEEP SUBCUTANEOUS
INJECTION
▶Child 6 months–17 years:(consult product literature or
local protocols)lUNLICENSED USENot licensed for use in children under
9 months.IMPORTANT SAFETY INFORMATION
MMR VACCINATION AND BOWEL DISEASE OR AUTISM
Reviews undertaken on behalf of the CSM, the Medical
Research Council, and the Cochrane Collaboration, have
not found any evidence of a link between MMR
vaccination and bowel disease or autism. The Chief
Medical Officers have advised that the MMR vaccine is
the safest and best way to protect children against
measles, mumps, and rubella. Information (including
fact sheets and a list of references) may be obtained from
http://www.dh.gov.uk/immunisation.lCAUTIONSAntibody response to measles component may
be reduced after immunoglobulin administration or blood
transfusion–leave an interval of at least 3 months before
MMR immunisation
CAUTIONS, FURTHER INFORMATION
▶Administration with other vaccinesMMR vaccine should not
be administered on the same day as yellow fever vaccine;
there should be a 4 -week minimum interval between the
vaccines. When protection is rapidly required, the vaccines
can be given at any interval and an additional dose of MMR
may be considered.
MMR and varicella-zoster vaccine can be given on the
same day or separated by a 4 -week minimum interval.
When protection is rapidly required, the vaccines can be
given at any interval and an additional dose of the vaccine
given second may be considered.
lINTERACTIONS→Appendix 1 : live vaccines
lSIDE-EFFECTS
▶UncommonIncreased risk of infection.rhinorrhoeaBNFC 2018 – 2019 Vaccination 799
Vaccines14